Psychopharmacology:酒精的气味可影响机体控制酒精摄入的能力

2016-03-22 MedSci MedSci原创

据发表于Psychopharmacology的一项新的研究表明,酒精的香味会减弱人们对自己饮酒行为的控制能力。

据发表于Psychopharmacology的一项新的研究表明,酒精的香味会减弱人们对自己饮酒行为的控制能力。

据美国疾病控制和预防中心(CDC)公布的统计数据显示,2010年至2012年在美国每天有六人因酒精中毒而死亡。其中,76%的人年龄在35-64岁之间,且76%的人为男性。

世界各国政府、社会团体和卫生部门正努力阻止人们摄入过量的酒精,因为摄入过量的酒精或可导致事故的发生,还可能产生长期的酒精依赖性。

美国卫生与人类服务部的女性健康办公室列出了一些对药物或酒精上瘾的原因。

其中包括基因、性别、种族,以及同行压力,应激压力和家庭问题。

酒精的作用取决于环境

近日,来自英国艾芝西尔大学的一项研究表明,即使是酒精的气味也可影响人们控制酒精的摄入能力,表明酒精的气味可吸引人们摄入酒精。

既往研究表明,与酒精摄入相关的行为与环境有关。这些研究发现看见酒精会唤醒机体引起唾液分泌。这类环境信息可导致酒精消耗量的变化,而且这类环境信息通常是在偶然间吸引住机体。机体摄入酒精量越多,他们对酒精相关信息的注意力越多。

本研究中,研究人员着手探究酒精相关的视觉与嗅觉信息如何影响机体酒精的摄入,换句话说,如何影响机体对酒精的注意力。

研究中研究对象戴着口罩,部分研究对象的口罩里含有酒精,而另一部分研究对象的口罩则含有非酒精性的柑桔液体。无论是看到屏幕上出现字母K还是一瓶瓶酒的图片时,研究对象需要按下一个按钮。

酒精的气味会产生更多的“假警报”

如果研究对象所按下的按钮不正确,那么则定为“假警报”,提示研究对象越来越难以控制自己的行为。

结果发现,佩戴含有酒精的口罩的研究对象更容易出现假警报的现象。

研究人员认为,看到或闻到酒精或可刺激机体的认知行为,从而增加酒精的消耗量。

艾芝西尔大学心理学高级讲师Dr. Rebecca Monk说道,“该研究首次尝试探索或可干扰机体控制某一特定行为能力的触发因子(如气味)。例如,在实验过程中,似乎仅有酒精的气味使得研究对象更难以控制自己的按键行为。”

该研究的共同作者Prof. Derek Heim补充道,这项研究或可为药物成瘾和药物滥用提供新的见解。他强调需要验证该试验结果,有必要在实验室外,在现实生活中来观察这些研究成果。

研究小组希望可以更好的了解特定的语境如何影响物质的使用,这将带来更适当的干预措施以帮助那些在不同环境中消费不同物质的人群。

原始出处:

Yvette Brazier. The smell of alcohol can affect behavior. Monday 21 March 2016.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=274883, encodeId=a6622e488367, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Jan 03 00:40:56 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995932, encodeId=75b0199593242, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 03 21:38:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042893, encodeId=9818204289301, content=<a href='/topic/show?id=981895492d6' target=_blank style='color:#2F92EE;'>#酒精摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95492, encryptionId=981895492d6, topicName=酒精摄入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Mon Oct 17 19:38:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787185, encodeId=70281e8718561, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu May 12 00:38:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788655, encodeId=04d41e8865543, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Mar 29 02:38:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908202, encodeId=deb21908202c8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Mar 28 13:38:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788173, encodeId=526a1e88173de, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 23:38:00 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2018-01-03 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=274883, encodeId=a6622e488367, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Jan 03 00:40:56 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995932, encodeId=75b0199593242, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 03 21:38:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042893, encodeId=9818204289301, content=<a href='/topic/show?id=981895492d6' target=_blank style='color:#2F92EE;'>#酒精摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95492, encryptionId=981895492d6, topicName=酒精摄入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Mon Oct 17 19:38:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787185, encodeId=70281e8718561, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu May 12 00:38:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788655, encodeId=04d41e8865543, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Mar 29 02:38:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908202, encodeId=deb21908202c8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Mar 28 13:38:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788173, encodeId=526a1e88173de, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 23:38:00 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-05-03 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=274883, encodeId=a6622e488367, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Jan 03 00:40:56 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995932, encodeId=75b0199593242, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 03 21:38:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042893, encodeId=9818204289301, content=<a href='/topic/show?id=981895492d6' target=_blank style='color:#2F92EE;'>#酒精摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95492, encryptionId=981895492d6, topicName=酒精摄入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Mon Oct 17 19:38:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787185, encodeId=70281e8718561, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu May 12 00:38:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788655, encodeId=04d41e8865543, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Mar 29 02:38:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908202, encodeId=deb21908202c8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Mar 28 13:38:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788173, encodeId=526a1e88173de, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 23:38:00 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=274883, encodeId=a6622e488367, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Jan 03 00:40:56 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995932, encodeId=75b0199593242, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 03 21:38:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042893, encodeId=9818204289301, content=<a href='/topic/show?id=981895492d6' target=_blank style='color:#2F92EE;'>#酒精摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95492, encryptionId=981895492d6, topicName=酒精摄入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Mon Oct 17 19:38:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787185, encodeId=70281e8718561, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu May 12 00:38:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788655, encodeId=04d41e8865543, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Mar 29 02:38:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908202, encodeId=deb21908202c8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Mar 28 13:38:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788173, encodeId=526a1e88173de, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 23:38:00 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-05-12 jj000001
  5. [GetPortalCommentsPageByObjectIdResponse(id=274883, encodeId=a6622e488367, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Jan 03 00:40:56 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995932, encodeId=75b0199593242, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 03 21:38:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042893, encodeId=9818204289301, content=<a href='/topic/show?id=981895492d6' target=_blank style='color:#2F92EE;'>#酒精摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95492, encryptionId=981895492d6, topicName=酒精摄入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Mon Oct 17 19:38:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787185, encodeId=70281e8718561, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu May 12 00:38:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788655, encodeId=04d41e8865543, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Mar 29 02:38:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908202, encodeId=deb21908202c8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Mar 28 13:38:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788173, encodeId=526a1e88173de, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 23:38:00 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=274883, encodeId=a6622e488367, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Jan 03 00:40:56 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995932, encodeId=75b0199593242, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 03 21:38:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042893, encodeId=9818204289301, content=<a href='/topic/show?id=981895492d6' target=_blank style='color:#2F92EE;'>#酒精摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95492, encryptionId=981895492d6, topicName=酒精摄入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Mon Oct 17 19:38:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787185, encodeId=70281e8718561, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu May 12 00:38:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788655, encodeId=04d41e8865543, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Mar 29 02:38:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908202, encodeId=deb21908202c8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Mar 28 13:38:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788173, encodeId=526a1e88173de, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 23:38:00 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=274883, encodeId=a6622e488367, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Jan 03 00:40:56 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995932, encodeId=75b0199593242, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 03 21:38:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042893, encodeId=9818204289301, content=<a href='/topic/show?id=981895492d6' target=_blank style='color:#2F92EE;'>#酒精摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95492, encryptionId=981895492d6, topicName=酒精摄入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Mon Oct 17 19:38:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787185, encodeId=70281e8718561, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu May 12 00:38:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788655, encodeId=04d41e8865543, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Mar 29 02:38:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908202, encodeId=deb21908202c8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Mar 28 13:38:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788173, encodeId=526a1e88173de, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 23:38:00 CST 2016, time=2016-09-26, status=1, ipAttribution=)]

相关资讯

多喝咖啡可降低肝硬化风险,多项证据证实

英国南安普敦大学的研究者对来自六个国家、近一百万男女的九项研究数据进行了荟萃分析,探究咖啡摄入量和肝硬化风险的关系。肝硬化常见于长期饮酒或肝炎病毒感染的患者,该疾病可导致肝衰竭和肝癌的发生,是严重威胁生命健康的疾病,也是全球性公共健康问题。因为很多未经诊断的患者的存在,导致现有的官方数据远低于实际情况。最新估计0.27%的美国人也就是633323名患有肝硬化,而其中69%的患者不知道自己有该疾病!

春节请不要喝这些下了”药“的酒

酒文化作为中华传统文化之一,素有“把酒谈心”、“把酒祝东风”的说法。春节归家,访亲问友、离家的时候总是少不了“喝一杯”的提议,最近网络上有个段子说:“喝酒不认真,此人是医生”。因为医生在喝酒的时候还在考虑药物与酒精的相互作用,还在担忧他们的病人有没有喝酒。药物和酒精都是通过肝脏代谢的,因此很容易相互作用,引发严重的不良反应:服用降压药后饮酒可使血管扩张,药物的降压作用增强,引起低血压;镇静药后

饮酒致癌,比你想象的更凶残!

很长的一段时间里,和酒精直接关联起来的癌症种类很少,这更是让人对酒精的致癌作用麻痹大意。似乎只要自夸一句“肝好”,就能把酒精的危害抛诸脑后。然而近些年的研究和追踪发现,酒精能引起的癌症并不局限于肝癌,而是从消化道到呼吸道到皮肤全面开花。 全面开花的致癌率 RehmJ等在2014年世界癌症报告中做出了一个统计——3.5%的癌症是由酒精造成的,同时每30个癌症死亡患者中就有一个是酒

IJC:每周喝3-5杯酒,可降低心脏病和心衰风险

对那些喜欢喝一杯酒的人来说,这是一个好消息:一周喝三到五杯酒,可以降低患心脏病和心力衰竭的风险。根据美国国家酒精滥用和酒精中毒研究所(NIAAA),87%的成年人在一生中喝过酒,超过56%人在过去的一个月里喝上了一杯。毫无疑问,过量饮酒对健康不利,但研究表明,适量饮酒可能会有好处。关于喝酒喝心脏病、心衰的两项研究由相同的团队进行。挪威科技大学 (NTNU)的Imre Janszky教授和团队对 6

Nat Genet:与酒精性肝硬化相关的数个遗传变异

在线发表于《自然—遗传学》上的一项研究公布了数个与重度饮酒者肝硬化或肝损伤风险增加有关的遗传变异。该研究揭示了饮酒导致的肝硬化和非饮酒因素导致的脂肪肝有着共同的遗传风险因素。 大多数重度饮酒者都会产生脂肪肝,但只有10%~15%会发展出肝硬化。先前研究认为,遗传对肝硬化患病风险有一定作用,但至今只有PNPLA3这一种基因被确定为相关的遗传变异。 Felix Stickel等人对来自

Circulation:适度饮酒会增加短期内心血管疾病风险吗?

哈佛大学公共卫生学院Elizabeth Mostofsky领导同事进行了这项研究,并将研究结果发表在Circulation。他们还将其发表在2016年美国心脏协会流行病学和预防科学会议。 既往研究已经探究过中重度饮酒与民众长期心血管疾病风险之间的关系,但很少人知道民众摄入酒精对其心血管疾病风险的短期影响。Mostofsky博士表示,这是第一个分析饮酒数小时后导致民众1周内出现急性心脏病发作和中风的